Mallinckrodt and Endo, drugmakers with a shared history of facing bankruptcy and U.S. opioid litigation, have agreed to merge ...
As per the Thursday release, Endo will be folded into Mallinckrodt, which will then continue as the holding entity for the ...
Mallinckrodt and Endo are merging in a cash and stock deal worth some $6.7 billion, the companies said Thursday. Under the ...
Endo shareholders will get $80 million in cash and own 49.9 per cent of the combined company, while Mallinckrodt shareholders ...
While Mallinckrodt emerged from its second bankruptcy in November 2023, Endo returned last year. The drugmakers are discussing the terms of a transaction that would give each of them roughly 50% ...
Mallinckrodt Pharmaceuticals and Endo Inc. plan to merge and create a $6.7 billion company in a move that will cut costs and broaden access to patients and new treatments.
Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S ...
The new entity will be listed on the New York Stock Exchange and is expected to generate pro forma revenue of $3.6 billion in ...